CMS advises Bruker on acquisition of UK pharmaceutical software business
CMS advised Nasdaq-listed Bruker Corporation on its acquisition of Optimal Industrial Automation and Technologies.
Massachusetts-headquartered Bruker’s life science diagnostic and research solutions enable scientists to make discoveries and develop new applications that improve the quality of human life.
Founded in 1987, Optimal focuses on the development, testing, deployment and support of quality-centric pharmaceutical production systems. The UK-based company has developed biopharmaceutical tools and automation capabilities that complement Bruker’s innovative solutions for drug discovery and development.
The CMS team was led by partner Graeme Bruce and a team of over 30 lawyers specializing in corporate, commercial, IP/IT, real estate, tax, employment, competition, pensions, health and safety, data protection, environment, litigation and banking. .
Dr. Falko Busse, Chairman of Bruker BioSpin Group, said: “We are delighted to have had the much appreciated support of Graeme and the CMS team in making this key acquisition a reality. Graeme and the team worked around the clock to ensure this transaction went smoothly and efficiently. This agreement marks a very exciting milestone for Bruker as it supports more comprehensive solutions for the biopharmaceutical industry, now adding the capabilities to integrate state-of-the-art systems into biopharmaceutical manufacturing processes and workflows.
Mr. Bruce said, “Bruker is a long-time CMS customer whose pioneering innovation in the life sciences industry improves human life. The acquisition of Optimal, an innovative UK-based pharmaceutical company, will further strengthen Bruker’s position as a global leader in drug discovery and development.
Optimal shareholders were represented by a team of attorneys from Thrings LLP led by Kate Westbrook and Elaine Meyrick.